Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL734545 | 0.92 | F2 (0.48) | F10F2KCNA5CYP1A2HTR1A | |
| SCHEMBL752717 | 0.91 | ALDH1A1 (0.43) | F10F2KCNA5RXRARXRB | |
| SCHEMBL733774 | 0.91 | MMP2 (0.42) | F10F2KCNA5RXRARXRB | |
| SCHEMBL731844 | 0.89 | CYP1A2 (0.38) | F10F2KCNA5RXRARXRB | |
| SCHEMBL731842 | 0.89 | CYP1A2 (0.38) | F10F2KCNA5RXRARXRB | |
| SCHEMBL734067 | 0.88 | RORC (0.41) | F10F2KCNA5CYP1A2 | |
| SCHEMBL731817 | 0.87 | CYP1A2 (0.47) | F10KCNA5CYP1A2ALDH1A1TP53 | |
| SCHEMBL731815 | 0.87 | CYP1A2 (0.47) | F10KCNA5CYP1A2ALDH1A1TP53 | |
| SCHEMBL732685 | 0.87 | CYP1A2 (0.39) | F10F2KCNA5CYP1A2ALDH1A1 | |
| SCHEMBL732687 | 0.87 | CYP1A2 (0.39) | F10F2KCNA5CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307383-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2012-05-16 | — | — | EP | claimed |
| US-8138208-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | claimed |
| JP-2011528004-A | — | — | 2011-11-10 | — | — | JP | claimed |
| EP-2307383-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | claimed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | claimed |
| WO-2010006944-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | claimed |
| US-8420675-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420675-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420675-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2307383-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2012-05-16 | — | — | EP | disclosed |
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | CHEN LI (CN) | 2012-04-26 | — | — | US | disclosed |
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | CHEN LI (CN) | 2012-04-26 | — | — | US | disclosed |
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | CHEN LI (CN) | 2012-04-26 | — | — | US | disclosed |
| US-8138208-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138208-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2307383-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| WO-2010006944-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | HRH2, HRH1, HRH4 | F10 736/4885F2 1418/4885KCNA5 1494/4885 |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | F10 736/4885F2 1418/4885KCNA5 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.